Tucatinib + trastuzumab + capecitabine for brain metastases
The one regimen proven in a randomised trial to help HER2-positive brain metastases, extending survival in those patients by six months.
HER2CLIMB: in patients with brain metastases, CNS-PFS HR 0.32 and OS 18.1 vs 12.0 months; response in untreated and treated lesions. Allows deferral of whole-brain radiation in selected cases.
Pages like this
not linked directly; found by shared links- IdeaSystemic-first management of HER2-positive brain metastases
Shares HER2CLIMB, HER2-positive brain metastases, Tucatinib, HER2-positive breast cancer.
- TrialHER2CLIMB-05
Shares Tucatinib, Trastuzumab, HER2-positive breast cancer.
- PersonNancy U. Lin
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- TrialHER2CLIMB-02
Shares Tucatinib, HER2-positive breast cancer.
- IdeaPrevention trials aimed only at brain metastasis
Shares HER2CLIMB, HER2-positive brain metastases, Tucatinib, HER2-positive breast cancer.
- IdeaStop excluding brain metastases from cancer trials
Shares HER2CLIMB, HER2-positive brain metastases.
- TrialDESTINY-Breast12
Shares HER2-positive brain metastases, HER2-positive breast cancer.
- TrialMOUNTAINEER & MOUNTAINEER-03
Shares Tucatinib, Trastuzumab.